|
1
|
Tunbridge WM, Evered DC, Hall R, Appleton
D, Brewis M, Clark F, Evans JG, Young E, Bird T and Smith PA: The
spectrum of thyroid disease in a community: The Whickham survey.
Clin Endocrinol (Oxf). 7:481–493. 1977.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Haugen BR: 2015 American thyroid
association management guidelines for adult patients with thyroid
nodules and differentiated thyroid cancer: What is new and what has
changed? Cancer. 123:372–381. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Al-Hilli Z, Strajina V, McKenzie TJ,
Thompson GB, Farley DR and Richards ML: The role of lateral neck
ultrasound in detecting single or multiple lymph nodes in papillary
thyroid cancer. Am J Surg. 212:1147–1153. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jee HG, Kim BA, Kim M, Yu HW, Choi JY, Kim
SJ and Lee KE: Expression of SLC5A5 in circulating tumor cells may
distinguish follicular thyroid carcinomas from adenomas:
Implications for blood-based preoperative diagnosis. J Clin Med.
8(257)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chin PD, Zhu CY, Sajed DP, Fishbein GA,
Yeh MW, Leung AM and Livhits MJ: Correlation of ThyroSeq results
with surgical histopathology in cytologically indeterminate thyroid
nodules. Endocr Pathol. 31:377–384. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nix P, Nicolaides A and Coatesworth AP:
Thyroid cancer review 2: Management of differentiated thyroid
cancers. Int J Clin Pract. 59:1459–1463. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nix PA, Nicolaides A and Coatesworth AP:
Thyroid cancer review 3: Management of medullary and
undifferentiated thyroid cancer. Int J Clin Pract. 60:80–84.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Roger VL, Go AS, Lloyd-Jones DM, Benjamin
EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, et al:
Executive summary: Heart disease and stroke statistics-2012 update:
A report from the American Heart Association. Circulation.
125:188–197. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lamartina L, Grani G, Durante C and
Filetti S: Recent advances in managing differentiated thyroid
cancer. F1000Res. 7(86)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Patrone R, Velotti N, Masone S, Conzo A,
Flagiello L, Cacciatore C, Filardo M, Granata V, Izzo F, Testa D,
et al: Management of low-risk thyroid cancers: Is active
surveillance a valid option? A systematic review of the literature.
J Clin Med. 10(3569)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Capdevila J, Galofre JC, Grande E, Zafon
Llopis C, Ramón Y, Cajal Asensio T, Navarro Gonzalez E,
Jiménez-Fonseca P, Santamaría Sandi J, Gómez Sáez JM and Riesco
Eizaguirre G: Consensus on the management of advanced radioactive
iodine-refractory differentiated thyroid cancer on behalf of the
Spanish society of endocrinology thyroid cancer working group
(GTSEEN) and Spanish rare cancer working group (GETHI). Clin Transl
Oncol. 19:279–287. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Barbet J, Campion L, Kraeber-Bodere F and
Chatal JF: Group GTES. Prognostic impact of serum calcitonin and
carcinoembryonic antigen doubling-times in patients with medullary
thyroid carcinoma. J Clin Endocrinol Metab. 90:6077–6084.
2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Perros P, Boelaert K, Colley S, Evans C,
Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles
TE, et al: Guidelines for the management of thyroid cancer. Clin
Endocrinol (Oxf). 81 (Suppl 1):S1–S122. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Miyauchi A, Kudo T, Miya A, Kobayashi K,
Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H,
et al: Prognostic impact of serum thyroglobulin doubling-time under
thyrotropin suppression in patients with papillary thyroid
carcinoma who underwent total thyroidectomy. Thyroid. 21:707–716.
2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Aya-Bonilla CA, Morici M, Hong X, McEvoy
AC, Sullivan RJ, Freeman J, Calapre L, Khattak MA, Meniawy T,
Millward M, et al: Detection and prognostic role of heterogeneous
populations of melanoma circulating tumour cells. Br J Cancer.
122:1059–1067. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sawabata N, Nakamura T, Kawaguchi T,
Watanabe T, Ouji NS, Ito T and Taniguchi S: Circulating tumor cells
detected only after surgery for non-small cell lung cancer: Is it a
predictor of recurrence? J Thorac Dis. 12:4623–4632.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cohen SJ, Punt CJ, Iannotti N, Saidman BH,
Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et
al: Relationship of circulating tumor cells to tumor response,
progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol. 26:3213–3221.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
de Bono JS, Scher HI, Montgomery RB,
Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ
and Raghavan D: Circulating tumor cells predict survival benefit
from treatment in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 14:6302–6309. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hayes DF, Cristofanilli M, Budd GT, Ellis
MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV and
Terstappen LW: Circulating tumor cells at each follow-up time point
during therapy of metastatic breast cancer patients predict
progression-free and overall survival. Clin Cancer Res.
12:4218–4224. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang PX, Xu Y, Sun YF, Cheng JW, Zhou KQ,
Wu SY, Hu B, Zhang ZF, Guo W, Cao Y, et al: Detection of
circulating tumor cells enables early recurrence prediction in
hepatocellular carcinoma patients undergoing liver transplantation.
Liver Int. 41:562–573. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Micalizzi DS, Haber DA and Maheswaran S:
Cancer metastasis through the prism of epithelial-to-mesenchymal
transition in circulating tumor cells. Mol Oncol. 11:770–780.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ehlers M, Allelein S, Schwarz F, Hautzel
H, Kuebart A, Schmidt M, Haase M, Dringenberg T and Schott M:
Increased numbers of circulating tumor cells in thyroid cancer
patients. Horm Metab Res. 50:602–608. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xu JY, Handy B, Michaelis CL, Waguespack
SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA Jr,
Cote GJ and Sherman SI: Detection and prognostic significance of
circulating tumor cells in patients with metastatic thyroid cancer.
J Clin Endocrinol Metab. 101:4461–4467. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Corbeil D, Fargeas CA and Huttner WB: Rat
prominin, like its mouse and human orthologues, is a pentaspan
membrane glycoprotein. Biochem Biophys Res Commun. 285:939–944.
2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Baker M: Cancer stem cells tracked.
Nature. 488:13–14. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Decaussin-Petrucci M, Deladoey J,
Hafdi-Nejjari Z, Sassolas G, Borson-Chazot F, Abu-Khudir R, Fusco
A, Descotes F, Cournoyer S and Sartelet H: group of Pathologists of
the Rhône Alpes Region. Expression of CD133 in differentiated
thyroid cancer of young patients. J Clin Pathol. 68:434–440.
2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang ZL, Zhang P, Li HC, Yang XJ, Zhang
YP, Li ZL, Xue L, Xue YQ, Li HL, Chen Q and Chong T: Dynamic
changes of different phenotypic and genetic circulating tumor cells
as a biomarker for evaluating the prognosis of RCC. Cancer Biol
Ther. 20:505–512. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Li J, Liao Y, Ran Y, Wang G, Wu W, Qiu Y,
Liu J, Wen N, Jing T, Wang H and Zhang S: Evaluation of sensitivity
and specificity of CanPatrol™ technology for detection of
circulating tumor cells in patients with non-small cell lung
cancer. BMC Pulm Med. 20(274)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hassan S, Blick T, Williams ED and
Thompson EW: Applications of RNA from circulating tumor cells.
Front Biosci (Landmark Ed). 25:874–892. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Syahrani RA, Yunita E and Wanandi SI:
Suppression of rotenone-treated human breast cancer stem cell
survival using survivin inhibitor YM155 is associated to oxidative
stress modulation. Asian Pac J Cancer Prev. 21:2631–2637.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Moon DH, Lindsay DP, Hong S and Wang AZ:
Clinical indications for, and the future of, circulating tumor
cells. Adv Drug Deliv Rev. 125:143–150. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Qiu ZL, Wei WJ, Sun ZK, Shen CT, Song HJ,
Zhang XY, Zhang GQ, Chen XY and Luo QY: Circulating tumor cells
correlate with clinicopathological features and outcomes in
differentiated thyroid cancer. Cell Physiol Biochem. 48:718–730.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Topa J, Gresner P, Zaczek AJ and
Markiewicz A: Breast cancer circulating tumor cells with
mesenchymal features-an unreachable target? Cell Mol Life Sci.
79(81)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Russo GI, Musso N, Romano A, Caruso G,
Petralia S, Lanzano L, Broggi G and Camarda M: The role of
dielectrophoresis for cancer diagnosis and prognosis. Cancers
(Basel). 14(198)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Satelli A, Batth I, Brownlee Z, Mitra A,
Zhou S, Noh H, Rojas CR, Li H, Meng QH and Li S: EMT circulating
tumor cells detected by cell-surface vimentin are associated with
prostate cancer progression. Oncotarget. 8:49329–49337.
2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hyun KA, Koo GB, Han H, Sohn J, Choi W,
Kim SI, Jung HI and Kim YS: Epithelial-to-mesenchymal transition
leads to loss of EpCAM and different physical properties in
circulating tumor cells from metastatic breast cancer. Oncotarget.
7:24677–24687. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li TT, Liu H, Li FP, Hu YF, Mou TY, Lin T,
Yu J, Zheng L and Li GX: Evaluation of epithelial-mesenchymal
transitioned circulating tumor cells in patients with resectable
gastric cancer: Relevance to therapy response. World J
Gastroenterol. 21:13259–13267. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang Y, Liu Y, Zhang L, Tong L, Gao Y, Hu
F, Lin PP, Li B and Zhang T: Vimentin expression in circulating
tumor cells (CTCs) associated with liver metastases predicts poor
progression-free survival in patients with advanced lung cancer. J
Cancer Res Clin Oncol. 145:2911–2920. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Vona G, Sabile A, Louha M, Sitruk V,
Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, et
al: Isolation by size of epithelial tumor cells: A new method for
the immunomorphological and molecular characterization of
circulatingtumor cells. Am J Pathol. 156:57–63. 2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Riethdorf S, Fritsche H, Muller V, Rau T,
Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, et al:
Detection of circulating tumor cells in peripheral blood of
patients with metastatic breast cancer: A validation study of the
CellSearch system. Clin Cancer Res. 13:920–928. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Qi LN, Xiang BD, Wu FX, Ye JZ, Zhong JH,
Wang YY, Chen YY, Chen ZS, Ma L, Chen J, et al: Circulating tumor
cells undergoing EMT provide a metric for diagnosis and prognosis
of patients with hepatocellular carcinoma. Cancer Res.
78:4731–4744. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Marcuello M, Vymetalkova V, Neves RPL,
Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G,
Garcia-Barberan V, Fijneman RJ, et al: Circulating biomarkers for
early detection and clinical management of colorectal cancer. Mol
Aspects Med. 69:107–122. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Allard WJ and Terstappen LW: CCR 20th
anniversary commentary: Paving the way for circulating tumor cells.
Clin Cancer Res. 21:2883–2885. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tieng FYF, Baharudin R, Abu N, Mohd Yunos
RI, Lee LH and Ab Mutalib NS: Single cell transcriptome in
colorectal cancer-current updates on its application in metastasis,
chemoresistance and the roles of circulating tumor cells. Front
Pharmacol. 11(135)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hou JM, Krebs MG, Lancashire L, Sloane R,
Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, et
al: Clinical significance and molecular characteristics of
circulating tumor cells and circulating tumor microemboli in
patients with small-cell lung cancer. J Clin Oncol. 30:525–532.
2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
de Sousa e Melo F, Kurtova AV, Harnoss JM,
Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z,
Koeppen H, et al: A distinct role for Lgr5(+) stem cells in primary
and metastatic colon cancer. Nature. 543:676–680. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Cefalu AB, Giammanco A, Noto D, Spina R,
Cabibi D, Barbagallo CM and Averna M: Effectiveness and safety of
lomitapide in a patient with familial chylomicronemia syndrome.
Endocrine. 71:344–350. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Proskurnina EV, Fedorova MV, Sozarukova
MM, Mitichkin AE, Panteleev IV and Svetlov EV: Microsomal reductase
activity in patients with thyroid neoplasms. Endocrine. 72:735–743.
2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zou X, Gao F, Wang ZY, Zhang H, Liu QX,
Jiang L, Zhou X and Zhu W: A three-microRNA panel in serum as novel
biomarker for papillary thyroid carcinoma diagnosis. Chin Med J
(Engl). 133:2543–2551. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Riegg F, Lutz MS, Schmied BJ, Heitmann JS,
Queudeville M, Lang P, Jung G, Salih HR and Märklin M: An
Fc-Optimized CD133 antibody for induction of NK cell reactivity
against B cell acute lymphoblastic leukemia. Cancers (Basel).
13(1632)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Liu Y, Yao X, Wang C, Wang M, Wang Y, Ye M
and Liu Y: Peptide-based 68Ga-PET radiotracer for imaging CD133
expression in colorectal cancer. Nucl Med Commun. 42:1144–1150.
2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Acikgoz E, Mukhtarova G, Alpay A, Avci CB,
Bagca BG and Oktem G: Sonic hedgehog signaling is associated with
resistance to zoledronic acid in CD133high/CD44high prostate cancer
stem cells. Mol Biol Rep. 48:3567–3578. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ge MH, Zhu XH, Shao YM, Wang C, Huang P,
Wang Y, Jiang Y, Maimaitiyiming Y, Chen E, Yang C and Naranmandura
H: Synthesis and characterization of CD133 targeted aptamer-drug
conjugates for precision therapy of anaplastic thyroid cancer.
Biomater Sci. 9:1313–1324. 2021.PubMed/NCBI View Article : Google Scholar
|
